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a b s t r a c t
Associations between the angiotensin II type 1 receptor (AGTR1) gene A1166C polymorphism
and hypertension, aortic abdominal aneurysms (as a risk factor) as well as cardiovascular
disorders (as a risk factor and an outcome predictor) have been demonstrated. We aimed to
investigate the role of this polymorphism as risk factors and outcome predictors in primary
intracerebral hemorrhage (PICH) and aneurysmal subarachnoid hemorrhage (aSAH).
We have prospectively recruited 1078 Polish participants to the study: 261 PICH patients,
392 aSAH patients, and 425 unrelated control subjects. The A1166C AGTR1 gene polymor-
phism was studied using the tetra-primer ARMS-PCR method. Allele and genotype frequen-
cies were compared with other ethnically different populations.
The A1166C polymorphism was not associated with the risk of PICH or aSAH. Among the
aSAH patients the AA genotype was associated with a good outcome, deﬁned by a Glasgow
Outcome Scale of 4 or 5 (p < 0.02). The distribution of A1166C genotypes in our cohort did not
differ from other white or other populations of European descent.
In conclusion, we found an association between the A1166C AGTR1 polymorphism and
outcome of aSAH patients, but not with the risk of PICH or aSAH.
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Stroke is one of the leading causes of death and disability.
Approximately 87% of all strokes are ischemic, 10% are
intracerebral hemorrhagic strokes (ICH) and the remaining
3% are subarachnoid hemorrhages (SAH) [1]. The latter are in
about 85% of aneurysmal origin (aSAH) [2]. The 30-day
mortality rate for aSAH is 32–45% [3,4] and for PICH is 35–
52% [5,6], with an overall one year mortality of 20–52% [1,6].
Thus, both hemorrhagic subtypes of stroke have more than
twice higher mortality rate than ischemic stroke (IS) and share
number of risk factors including hypertension (HT), smoking,
and alcohol abuse.
Angiotensin II receptor type 1 (AGTR1), encoded by the
AGTR1 gene is the ﬁrst of two angiotensin II (AII) receptors. AII
is a crucial neurohormone in the renin–angiotensin–aldoste-
rone system and plays an important role in the pathophysiol-
ogy of HT. The CC genotype of the A1166C single nucleotide
polymorphism (SNP) (ID: rs5186) of the AGTR1 gene has been
shown to increase the response to AII, resulting in an
increased risk of cardiovascular disease [7].
C allele or CC genotype of the A1166C polymorphism were
found to be associated with an increased risk of hypertension
(C allele) [8], aortic stiffness (CC genotype) [9], left ventricular
hypertrophy (C allele) [10], myocardial infarction (CC genotype)
[11], and abdominal aortic aneurysm (C allele) [12]. Recently,
this polymorphism has also been recognized as an outcome
predictor in two groups of patients with cardiovascular
diseases. In patients after percutaneous coronary intervention
it was associated with long term clinical outcome deﬁned as
death, repeat revascularization and myocardial infarction [13].
In heart failure and reduced systolic function it was associated
with poor prognostic markers and increased mortality [14].
Results of a recent meta-analysis indicate that the A1166C
polymorphism is not associated with susceptibility to IS [15].
These ﬁndings were adjusted to the variability of allele
distribution across ethnically different populations. To the
best of our knowledge the signiﬁcance of this polymorphism
has only been studied in two, small groups of hemorrhagic
stroke patients (<50 subjects), where hemorrhagic stroke
etiology was not assessed [16,17].
The aim of this study was to evaluate the role of A1166C
AGTR1 gene polymorphism as risk factors and outcome
predictors in two types of hemorrhagic stroke i.e., PICH and
aSAH among Polish patients. An additional analysis of allele
distribution across various ethnic groups was also carried out.
2. Materials and methods
This study was approved by the Ethical Committee of the
Jagiellonian University.
2.1. Study subjects
After full and signed informed consent given by study
subjects or their family member, 1078 participants were
enrolled to the study. 261 PICH and 392 aSAH patients were
prospectively recruited from subjects consecutively admittedto the Department of Neurology or Neurosurgery and
Neurotraumatology, University Hospital Krakow, Poland
between 2002 and 2010. PICH was diagnosed based on non-
contrast cranial computed tomography (CT). Patients with
secondary intracerebral hemorrhage (SICH) due to vascular
malformations, head trauma, brain tumor, hematologic
abnormalities or hemorrhagic transformation of IS were
excluded. SAH was diagnosed by cranial CT and/or lumbar
puncture. The diagnosis of a saccular aneurysm was
established by digital subtraction angiography or angio-CT.
Only patients with non-traumatic aSAH were included into
the study. Details on aSAH and PICH patients recruitment are
provided in a Supplementary Figure 1. 425 unrelated control
subjects free from cerebrovascular and neurological diseases
were recruited from the relatives of hospital staff, patients of
the University Hospital hospitalized for any reason other than
neurological diseases and spouses of the patients of the
Department of Neurology. Demographic and risk factor
proﬁles were collected using a questionnaire described
previously [18,19]. In particular, we have collected informa-
tion on age, gender, race, HT, hypercholesterolemia, obesity,
diabetes mellitus and current smoking. Glasgow Outcome
Scale (GOS) was assessed for PICH and aSAH patients at
discharge. Good outcome was deﬁned as a GOS of 4 or 5,
whereas poor outcome was deﬁned as a GOS of 1–3.
Supplementary Figure 1 related to this article can be found,
in the online version, at doi:10.1016/j.pjnns.2014.07.007.
2.2. Genotyping
Uncuffed venous blood samples for extraction of DNA were
drawn from each subject within a week from enrollment.
Leukocyte DNA was extracted using a commercially available
kit (High Pure PCR template Preparation Kit; Boehringer
Mannheim). The A1166C AGTR1 gene polymorphism was
studied using the tetra-primer ARMS-PCR method, adapted
from Ye et al. [20].
2.3. Statistical analysis
Study power for A1166C polymorphism both for PICH and
aSAH groups was calculated. Rare homozygote and heterozy-
gote (CC, AC) were combined and tested vs common
homozygote (AA). aSAH power analysis revealed that a study
of this size has 80% power at a type I error probability of
alpha = 0.05 to detect a 10% difference between tested
populations. PICH power analysis revealed that a study of
this size has 80% power at a type I error probability alpha = 0.05
to detect a 13% difference between tested populations.
Differences between patients and controls for continuous
data were tested with Student's t-test. Categorical variables
were tested with x2 test or Fisher exact test (where applicable).
The deviation from Hardy–Weinberg equilibrium for tested
polymorphism was examined by x2 test. To measure the
associations between studied allele or genotypes and selected
variables odds ratios (OR) and 95% conﬁdence intervals (95% CI)
were calculated. Logistic regression analysis was used to test
hypotheses about relations between categorical binominal
variables and one or more categorical or continuous predictor
variables. A value of p < 0.05 was considered signiﬁcant.
Table 1 – Characteristics of the study subjects.
Control subjects
(CS) (n = 425)
aSAH patients
(n = 392)
PICH patients
(n = 261)
p
aSAH vs CS
p
PICH vs CS
Age, years; mean (SD) 64.15 (12.05) 51.23 (12.63) 66.12 (13.54) <0.001 ns
Gender, male 60.5% 57.5% 50.6% ns <0.05
HT 48.8% 61% 79% <0.001 <0.001
Hypercholesterolemia 35.6% 21% 38% <0.001 ns
Obesity 20.9% 13.4% 24.2% <0.05 ns
Diabetes mellitus 12% 7.7% 17% ns ns
Current smoking 19.9% 47.2% 28.9% <0.001 <0.05
aSAH, aneurysmal subarachnoid hemorrhage; PICH, primary intracerebral hemorrhage; SD, standard deviation; HT, hypertension; ns, non
signiﬁcant; p values were obtained with t-test (age) and Fisher exact test (rest of variables).
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The demographic data and risk factor proﬁles of patients and
controls are presented in Table 1. The control group was older
than the aSAH group but not when compared to the PICH
group. In comparison to the control group, the percentage of
females was higher in the PICH group, but not different to the
aSAH group.
The allele distribution of the investigated polymorphism
did not deviate from Hardy–Weinberg equilibrium for the
controls, PICH or aSAH patients. The frequencies of the studied
genotypes and alleles were similar in all of the stroke patients
and control subjects (Table 2).
In logistic regression analysis, the recessive genotype – AA vs
AC and CC – was the independent variable and age, gender, HT,
and GOS outcome were the dependent variables. Results are
presented in Table 3. In the aSAH group AA carriers had better
outcome (OR = 1.62; p < 0.02) and were more likely to be older
(OR = 1.02; p < 0.03). After adjustment for HT the results
remained signiﬁcant for GOS of 4–5 (OR = 1.89; 95% CI: 1.01–
3.54, p = 0.04). A validation model where logistic regression
analysis was adjusted to (GOS, age, gender, smoking and
hypercholesterolemia) conﬁrmed our ﬁndings, AA carriers had
better outcome (OR = 1.44; 95% CI: 1.08–1.91, p = 0.01) and were
more likely to be younger (OR = 1.07; 95% CI: 1.03–1.1, p < 0.001).
The results of comparisons between genotype and allele
distributions in our control group and groups of different
ethnicity are summarized in Fig. 1. Our Polish cohort does not
differ from New Zealand, United Kingdom, Western Australian
and white American cohorts [12,18]. In contrast, African
American, Chinese, and Japanese cohorts, which were similar
to each other, signiﬁcantly differ in allele and genotypeTable 2 – The AGTR1 gene A1166C polymorphism: genotypes a
patients.
Control subjects
(CS) (n = 425)
aSAH patients
(n = 392)
PICH patie
(n = 261
AA 51.6% 52.6% 55.9% 
AC 35.8% 41.6% 39.1% 
CC 5.9% 5.9% 5% 
A 69.6% 73.3% 75.5% 
aSAH, aneurysmal subarachnoid hemorrhage; PICH, primary intracerebradistribution when compared with the studied Polish popula-
tion (p < 0.0001) [21–23].
4. Discussion
There are three major ﬁndings in the present study of the
A1166C AGTR1 gene polymorphism in hemorrhagic strokes: (1)
the A1166C polymorphism is not associated with the risk of
PICH or aSAH, (2) AA genotype is associated with better
outcome in aSAH patients, and (3) A1166C distribution varies
across populations of different ethnicity.
Analyses performed within studied stroke groups revealed
interesting results for aSAH patients. Contrary to CC and AC
genotypes, AA homozygotes in the aSAH group were more likely
to have good outcomes (GOS 4–5).Although A1166Cis not directly
associated with stroke risk it correlates with stroke outcome in
the aSAH group. Its effect on outcome was also shown in patients
after percutaneous coronary interventions and in patients with
heart failure and reduced systolic function patient [13,14]. Based
on mice models several authors have shown that interaction of
AII with activated T leukocytes contributes to T-cell cytokine
production and tissue invasion [24–26]. Since A1166C is a
functional polymorphism, with CC genotype being related both
to increased response to AII and to worse clinical outcomes, we
speculate that C allele may be related to the delayed vascular
damage, and in effect, aSAH outcome.
According to our knowledge this is the ﬁrst paper to assess
the role of the A1166C AGTR1 gene polymorphism in two
hemorrhagic stroke etiologies: aSAH and PICH. Although A1166C
is associated with hypertension, a major risk factor for both
aSAH (OR = 2.6) [27] and PICH (OR = 5.7) [28], it was not associated
with the risk of the stroke etiologies studied. Our results andnd allele frequencies in control subjects, aSAH and PICH
nts
)
p
aSAH vs CS
p
PICH vs CS
p
aSAH vs PICH
ns ns ns
ns ns ns
ns ns ns
ns ns ns
l hemorrhage; ns, non signiﬁcant; p values were obtained with x2 test.
Fig. 1 – Comparison of AGRT1 gene A1166C genotypes and allele frequencies across different populations of different
ethnicity. Frequencies of genotypes and alleles observed in control group in our study (Polish) were compared to frequencies
in control groups observed in studies by Jones et al. [12] (New Zeland, United Kingdom, Western Australian), Hindorff et al.
[18] (White Americans, African American), Thomas et al. [19] (Chinese), Akasaka et al. [20] (Japanese). *Significant difference
( p < 0.05) based on x2 test.
Table 3 – Logistic regression analysis.
AA vs AC and CC PICH, OR (95% CI); p aSAH, OR (95% CI); p Control subjects,
OR (95% CI); p
GOS 4–5 0.99 (0.57–1.73); ns 1.62 (1.05–2.50); 0.02 –
HT 1.28 (0.63–2.59); ns 0.86 (0.56–1.31); ns 0.77 (0.52–1.13); ns
Age 1.00 (0.98–1.02); ns 1.02 (1.00–1.04); 0.03 1.00 (0.98–1.02); ns
Male gender 1.71 (0.96–3.03); 0.06 0.79 (0.52–1.20); ns 1.04 (0.70–1.52); ns
aSAH, aneurysmal subarachnoid hemorrhage; PICH, primary intracerebral hemorrhage; GOS, Glasgow Outcome Scale; HT, hypertension; OR,
odds ratio; CI, conﬁdence interval; ns, non signiﬁcant; OR, 95% CI and p-values were obtained with simple logistic regression analysis; AA vs AC
and CC genotype was the independent variable.
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A1166C polymorphism does not affect the risk of stroke [27,28].
We have compared allele and genotype distributions
between the current Polish control group and a number of
control groups of different ethnicity and race (Fig. 1). Our control
group was not different to a control group from the United
Kingdom, white Americans, or Western Australian and New
Zealand groups. In contrast, Chinese, Japanese and African
American groups showed signiﬁcantly different allele and
genotype distributions from our control group. According to
the NCBI SNP database [29], the frequency of the C allele in Asian
and African American populations is below 10%, whereas in
White populations it is above 25%. Our analysis and NCBI data
on SNP distribution suggest that our ﬁndings may be applicable
to white or populations of European descent but that African
and Asian group should be analyzed separately.
There are several potential limitations of our study. First,
control subjects were not perfectly matched to the hemor-
rhagic patients. Due to a signiﬁcant difference between the
mean age of the aSAH and PICH groups we have chosen to
recruit older subjects to the control group in order to match to
the PICH group. The proportion of males in the control group
was 10% higher than in the ICH group. However, in logistic
regression analysis neither age nor gender was associated
with genotype distribution in the control group, and therefore
we do not expect that these differences could affect our
results. The difference in the average allele and genotype
distribution between the control group and the PICH or aSAH
groups ranged from 1 to 6%. In order to conﬁrm the lack of
difference in allele and genotype distribution with these
numbers, at a power of 80% (b = 0.8) and a = 0.05, the study
groups would need to be increased to more than 39,000
participants. Finally, due to relatively small sample size of
aSAH patients association between the polymorphism and
good outcome may be false positive. Therefore replication in
an independent cohort is needed to conﬁrm our ﬁnding.
In conclusion we found an association between the AA
genotype of the A1166C AGTR1 gene polymorphism and good
outcome among aSAH patients. Our results suggest that there
is no associations of this polymorphism with the risk of either
PICH or aSAH stroke in a Polish population.
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